$WHG

Westwood Holdings Group (NYSE:WHG) Director Sells $12,211.78 in Stock

Westwood Holdings Group Director Susan Byrne sold 733 shares of WHG stock for $12,211.78, reducing her stake by 0.25% to 293,276 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently declared a quarterly dividend of $0.15, and Weiss Ratings reiterated a "buy" rating on the stock.

Original reporting
MarketBeat · MarketBeat
Published Apr 30, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Westwood Holdings Group (NYSE:WHG) Director Sells $12,211.78 in Stock — source image
Decision brief

The 30-second read

$WHGBearishLow
01

Why it matters

While insider sales can signal caution, they are not definitive indicators of future stock performance, especially when aligned with positive analyst ratings and dividends.

02

Market read

The news has limited immediate impact on the broader market but provides insight into insider activity at WHG.

03

What to watch

Potential for the stock to rebound if the insider sale was motivated by personal liquidity needs rather than negative outlook.

Relevance 6/10Timing: short-term

Background

The director's sale was executed under a pre-arranged trading plan, which is often routine.

Company-level read

Ticker impact

$WHGBearishMedium confidence
Context

Recent insider stock sale and analyst rating

Expected impact

Minor downward pressure expected in the short term, with long-term stability if fundamentals remain strong.

Evidence & confidence

The insider sale reduces insider ownership slightly, which can be perceived as a cautionary signal; however, the company's dividend and analyst rating support a neutral to slightly bearish outlook.

Market effects

Minimal impact on the financial sector

Limited regional influence

Negligible

Counterpoint

The insider sale may be routine and not indicative of future performance; the company’s fundamentals remain strong.

Key entities

  • Susan Byrne

    Director of Westwood Holdings Group

  • Westwood Holdings Group

    Asset management firm listed on NYSE

Related articles

$WHGMed

Westwood Holdings (WHG) Q2 2026 Earnings Call Transcript

Westwood Holdings Group (WHG) reported Q2 2026 revenues of $25.3 million and net income of $1.5 million, or $0.17 per diluted share. Economic earnings were $3.0 million, or $0.33 per share. Assets under management were $17.0 billion after $1.6 billion net outflows. The firm said its ETF, private capital, and managed solutions segments each exceed $500 million and noted the PWRX ETF will list mid-September on the Texas Stock Exchange.

$WHGMed

Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results

WESTWOOD HOLDINGS GROUP INC (WHG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Westwood Holdings Group, Inc. Reports Second Quarter 2026 Results Private Capital platform surpassed $500 million in assets Managed Investment Solutions flows reached $350 million Dallas, TX, August 6, 2026 – Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter

$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.